Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases ...
The British pharma giant will hand off its experimental itch treatment to Italian company Alfasigma as it focuses on broader ...
Pharmaceutical Technology on MSN
GSK sells liver disease drug candidate to Alfasigma for $690m
GSK’s linerixibat is currently under regulatory review in the US, Europe, and China, amongst other regions.
Peking University, October 30, 2024: Addressing the challenge of cholestatic itch, the scientific community has been pursuing innovative solutions. Recently, researchers from Peking University, led by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results